Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Popov

Showing results (111-120 of 135) with videos related to

Pageof 14
Sort By:
Reproductive Medicine and Biology|September 13, 2023
The Asian Society of Endometriosis and Adenomyosis guidelines for managing adenomyosisTasuku Harada, Fuminori Taniguchi, Sun-Wei Guo, et al.
Cancers|December 9, 2023
A Single Dose of PEG-Asparaginase at the Beginning of Induction Not Only Accelerates MRD Clearance but Also Improves Long-Term Outcome in Children with B-Lineage ALLAlexander Popov, Günter Henze, Julia Roumiantseva, et al.
British Journal of Haematology|December 31, 2021
Comparison of minimal residual disease measurement by multicolour flow cytometry and PCR for fusion gene transcripts in infants with acute lymphoblastic leukaemia with KMT2A gene rearrangementsAlexander Popov, Grigory Tsaur, Tatiana Verzhbitskaya, et al.
Science (New York, N.Y.)|May 6, 2017
Impact of cytosine methylation on DNA binding specificities of human transcription factorsYimeng Yin, Ekaterina Morgunova, Arttu Jolma, et al.
Science Advances|September 27, 2017
Inward H<sup>+</sup> pump xenorhodopsin: Mechanism and alternative optogenetic approachVitaly Shevchenko, Thomas Mager, Kirill Kovalev, et al.
Leukemia|March 24, 2022
A simple algorithm with one flow cytometric MRD measurement identifies more than 40% of children with ALL who can be cured with low-intensity therapy. The ALL-MB 2008 trial resultsAlexander Popov, Guenter Henze, Julia Roumiantseva, et al.
Leukemia Research|November 4, 2022
A single flow cytometric MRD measurement in children with B-lineage acute lymphocytic leukemia and hyperleukocytosis redefines the requirements of high-risk treatment: Results of the study ALL-MB 2008Alexander Popov, Guenter Henze, Julia Roumiantseva, et al.
Journal of Cancer Research and Clinical Oncology|September 28, 2022
One-point flow cytometric MRD measurement to identify children with excellent outcome after intermediate-risk BCP-ALL: results of the ALL-MB 2008 studyAlexander Popov, Guenter Henze, Julia Roumiantseva, et al.
Pediatric Blood & Cancer|March 28, 2023
A simple procedure to identify children with B-lineage acute lymphoblastic leukemia who can be successfully treated with low or moderate intensity: Sequential versus single-point minimal residual disease measurementAlexander Popov, Guenter Henze, Julia Roumiantseva, et al.
Cancer Medicine|April 23, 2024
Flow cytometric minimal residual disease measurement accounting for cytogenetics in children with non-high-risk acute lymphoblastic leukemia treated according to the ALL-MB 2008 protocolAlexander Popov, Guenter Henze, Grigory Tsaur, et al.
Pageof 14

Showing results (111-120 of 135) with videos related to

Sort By:
Pageof 14
Reproductive Medicine and Biology|September 13, 2023
The Asian Society of Endometriosis and Adenomyosis guidelines for managing adenomyosisTasuku Harada, Fuminori Taniguchi, Sun-Wei Guo, et al.
Cancers|December 9, 2023
A Single Dose of PEG-Asparaginase at the Beginning of Induction Not Only Accelerates MRD Clearance but Also Improves Long-Term Outcome in Children with B-Lineage ALLAlexander Popov, Günter Henze, Julia Roumiantseva, et al.
British Journal of Haematology|December 31, 2021
Comparison of minimal residual disease measurement by multicolour flow cytometry and PCR for fusion gene transcripts in infants with acute lymphoblastic leukaemia with KMT2A gene rearrangementsAlexander Popov, Grigory Tsaur, Tatiana Verzhbitskaya, et al.
Science (New York, N.Y.)|May 6, 2017
Impact of cytosine methylation on DNA binding specificities of human transcription factorsYimeng Yin, Ekaterina Morgunova, Arttu Jolma, et al.
Science Advances|September 27, 2017
Inward H<sup>+</sup> pump xenorhodopsin: Mechanism and alternative optogenetic approachVitaly Shevchenko, Thomas Mager, Kirill Kovalev, et al.
Leukemia|March 24, 2022
A simple algorithm with one flow cytometric MRD measurement identifies more than 40% of children with ALL who can be cured with low-intensity therapy. The ALL-MB 2008 trial resultsAlexander Popov, Guenter Henze, Julia Roumiantseva, et al.
Leukemia Research|November 4, 2022
A single flow cytometric MRD measurement in children with B-lineage acute lymphocytic leukemia and hyperleukocytosis redefines the requirements of high-risk treatment: Results of the study ALL-MB 2008Alexander Popov, Guenter Henze, Julia Roumiantseva, et al.
Journal of Cancer Research and Clinical Oncology|September 28, 2022
One-point flow cytometric MRD measurement to identify children with excellent outcome after intermediate-risk BCP-ALL: results of the ALL-MB 2008 studyAlexander Popov, Guenter Henze, Julia Roumiantseva, et al.
Pediatric Blood & Cancer|March 28, 2023
A simple procedure to identify children with B-lineage acute lymphoblastic leukemia who can be successfully treated with low or moderate intensity: Sequential versus single-point minimal residual disease measurementAlexander Popov, Guenter Henze, Julia Roumiantseva, et al.
Cancer Medicine|April 23, 2024
Flow cytometric minimal residual disease measurement accounting for cytogenetics in children with non-high-risk acute lymphoblastic leukemia treated according to the ALL-MB 2008 protocolAlexander Popov, Guenter Henze, Grigory Tsaur, et al.
Pageof 14